Junyuan Wang
Bristol-Myers Squibb
6 Papers
96 Citations
Junyuan Wang is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Apixaban & Warfarin. The author has an hindex of 3, co-authored 6 publications. Previous affiliations of Junyuan Wang include Merck Serono.
Chat about Author
Papers
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Christopher B. Granger,Renato D. Lopes,Michael G. Hanna,Jack Ansell,Elaine M. Hylek,John H. Alexander,Laine Thomas,Junyuan Wang,M. Cecilia Bahit,Freek W.A. Verheugt,Jack Lawrence,Denis Xavier,Lars Wallentin +12 more
TL;DR: In the ARISTOTLE trial as discussed by the authors, the authors evaluated the occurrence of events after blinded study drug discontinuation and transition to open-label vitamin K antagonist (VKA), and found that the excess in thrombotic and bleeding events in the apixaban group was related to an increased risk associated with the initiation of a VKA rather than a direct effect of apixaba.
70
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Christopher B. Granger,John H. Alexander,Michael G. Hanna,Junyuan Wang,Puneet Mohan,Jack Lawrence,Elaine M. Hylek,Jack Ansell,Lars Wallentin +8 more
TL;DR: It was demonstrated that the participation of GPs as the core in the multi-disciplinary team to provide hypertension management care at the community level was both effective and feasible in meeting the health care needs of hypertensive population and also improving control of cardiovascular risk factors.
Documentation of study medication dispensing in a prospective large randomized clinical trial : Experiences from the ARISTOTLE Trial
John H. Alexander,Elliott Levy,Jack Lawrence,Michael G. Hanna,Anthony P. Waclawski,Junyuan Wang,Robert M. Califf,Lars Wallentin,Christopher B. Granger +8 more
TL;DR: In the ARISTOTLE trial, the rate of medication dispensing error resulting in treatment error was 0.04% as mentioned in this paper and 1.2% of subjects in the warfarin group received at least 1 incorrect container of the wrong type.
10
Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect
Patrícia O. Guimarães,Renato D. Lopes,Daniel Wojdyla,Azmil H. Abdul-Rahim,Stuart J. Connolly,Greg C. Flaker,Junyuan Wang,Michael G. Hanna,Christopher B. Granger,Lars Wallentin,Kennedy R. Lees,John H. Alexander,John J.V. McMurray +12 more
TL;DR: In patients with AF, indirect comparisons suggest that apixaban reduces all-cause death by approximately one third compared with an imputed placebo.
Effect of apixaban on all-cause mortality in atrial fibrillation : an imputed placebo analysis
Jjv McMurray,Stuart J. Connolly,Robert G. Hart,Gregory C. Flaker,Renato D. Lopes,Junyuan Wang,Michael G. Hanna,John H. Alexander,Christopher B. Granger,Lars Wallentin +9 more
TL;DR: This imputed placebo analysis suggests that apixaban significantly reduces all-cause mortality by about one-third in patients with AF.
3